Journal of Hepatology
Volume 48, Issue 5 , Pages 708-713 , May 2008

Hepatic gene expression and prediction of therapy response in chronic hepatitis C patients

  • Nazia Selzner

      Affiliations

    • Multiorgan Transplant Program, University Health Network, University of Toronto, 11C 1250 Toronto General Hospital, 585 University Avenue, Toronto, Ont., Canada M5G 2N2
    • ,
  • Limin Chen

      Affiliations

    • Banting and Best Department of Medical Research, University of Toronto, Toronto, Canada
    • ,
  • Ivan Borozan

      Affiliations

    • Banting and Best Department of Medical Research, University of Toronto, Toronto, Canada
    • ,
  • Aled Edwards

      Affiliations

    • Banting and Best Department of Medical Research, University of Toronto, Toronto, Canada
    • ,
  • E. Jenny Heathcote

      Affiliations

    • Department of Medicine, University of Toronto, Toronto, Canada
    • ,
  • Ian McGilvray

      Affiliations

    • Multiorgan Transplant Program, University Health Network, University of Toronto, 11C 1250 Toronto General Hospital, 585 University Avenue, Toronto, Ont., Canada M5G 2N2
    • Banting and Best Department of Medical Research, University of Toronto, Toronto, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1 416 340 5230; fax: +1 416 340 5242.

References 

  1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171
  2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  4. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  5. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology. 1999;30:787–793
  6. Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat. 2001;8:264–269
  7. De Maria N, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology. 2002;49:788–792
  8. Missiha S, Heathcote J, Arenovich T, Khan K Canadian Pegasys Expanded Access Group. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol. 2007;102:2181–2188
  9. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut. 2006;55:529–535
  10. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology. 2002;36:S185–S194
  11. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 2000;31:211–218
  12. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343:1673–1680
  13. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645–652
  14. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97–103
  15. Gallegos-Orozco JF, Loaeza-del Castillo A, Fuentes AP, Garcia-Sandoval M, Soto L, Rodriguez R, et al. Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin. Liver Int. 2005;25:91–95
  16. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005;128:1437–1444
  17. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology. 2007;46:1548–1563
  18. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut. 2007;
  19. Chen L, Bronzan I, Sun J, Anand N, Heathcote EJ, Edwards A, et al. Validation of a gene signature predicting response to treatment in chronic hepatitis C virus infection. Hepatology. 2007;46:256A
  20. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology. 2006;131:1584–1591
  21. Hayashida K, Daiba A, Sakai A, Tanaka T, Kaji K, Inaba N, et al. Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2005;3:1253–1259
  22. Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, Huang DW, et al. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis. 2006;193:1172–1177
  23. Feld J, Fried MW, Liang TJ. Gene expression in liver during interferon therapy in humans. In: American association for the study of liver diseases, hepatitis single topic conference, interferon and ribavirin in hepatitis C virus infection: mechanisms of response and non-response, 2003 March 1–3, Chicago, IL.
  24. Gerotto M, Dal Pero F, Bartoletto G, Reoldan S, Ferrari A, Baccato S, et al. PKR gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C. Antivir Ther. 2004;9:763–770
  25. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol. 2007;81:3391–3401
  26. Rocha D, Gut I, Jeffreys AJ, Kwok PY, Brookes AJ, Chanock SJ. Seventh international meeting on single nucleotide polymorphism and complex genome analysis: ‘ever bigger scans and an increasingly variable genome’. Hum Genet. 2006;119:451–456
  27. Brookes AJ. The essence of SNPs. Gene. 1999;234:177–186
  28. Nickerson DA, Taylor SL, Weiss KM, Clark AG, Hutchinson RG, Stengard J, et al. DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. Nat Genet. 1998;19:233–240
  29. Houldsworth A, Metzner M, Rossol S, Shaw S, Kaminski E, Demaine AG, et al. Polymorphisms in the IL-12B gene and outcome of HCV infection. J Interferon Cytokine Res. 2005;25:271–276
  30. Suzuki F, Arase Y, Suzuki Y, Tsubota A, Akuta N, Hosaka T, et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat. 2004;11:271–276
  31. Abbas Z, Moatter T, Hussainy A, Jafri W. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol. 2005;11:6656–6661
  32. Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt −88) correlated with the response of hepatitis C patients to interferon. Intervirology. 2000;43:124–127
  33. Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003;4:411–419
  34. Naito M, Matsui A, Inao M, Nagoshi S, Nagano M, Ito N, et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol. 2005;40:381–388
  35. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology. 2004;39:880–890
  36. Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology. 2002;35:694–703
  37. Woollard DJ, Grakoui A, Shoukry NH, Murthy KK, Campbell KJ, Walker CM. Characterization of HCV-specific Patr class II restricted CD4+ T cell responses in an acutely infected chimpanzee. Hepatology. 2003;38:1297–1306
  38. Huang Y, Yang H, Borg BB, Su X, Rhodes SL, Yang K, et al. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA. 2007;104:985–990
  39. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology. 2001;33:708–712

☆ The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(08)00125-6

doi: 10.1016/j.jhep.2008.02.010

Journal of Hepatology
Volume 48, Issue 5 , Pages 708-713 , May 2008

Article Tools